STABLON

Stablon Adverse Events Reported to the FDA Over Time

How are Stablon adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Stablon, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Stablon is flagged as the suspect drug causing the adverse event.

Most Common Stablon Adverse Events Reported to the FDA

What are the most common Stablon adverse events reported to the FDA?

Hyponatraemia	24 (2.46%)
Fall	21 (2.16%)
Pyrexia	21 (2.16%)
Dehydration	18 (1.85%)
Diarrhoea	18 (1.85%)
Confusional State	17 (1.75%)
Cytolytic Hepatitis	17 (1.75%)
Dysphagia	15 (1.54%)
Vomiting	15 (1.54%)
Agranulocytosis	14 (1.44%)
Cholestasis	14 (1.44%)
	Show More
Eosinophilia	13 (1.33%)
Cough	12 (1.23%)
Chills	11 (1.13%)
Nausea	11 (1.13%)
Pancytopenia	11 (1.13%)
Pruritus	11 (1.13%)
Rash Morbilliform	11 (1.13%)
Food Intolerance	10 (1.03%)
Musculoskeletal Chest Pain	8 (.82%)
Oxygen Saturation Decreased	8 (.82%)
Skin Exfoliation	8 (.82%)
Suicide Attempt	8 (.82%)
Hypertension	7 (.72%)
International Normalised Ratio Incr...	7 (.72%)
Malaise	7 (.72%)
Rash Maculo-papular	7 (.72%)
Renal Failure	7 (.72%)
Bacteraemia	6 (.62%)
Cerebellar Haematoma	6 (.62%)
Disorientation	6 (.62%)
Drug Eruption	6 (.62%)
Epilepsy	6 (.62%)
Fatigue	6 (.62%)
General Physical Health Deteriorati...	6 (.62%)
Guillain-barre Syndrome	6 (.62%)
Ischaemic Stroke	6 (.62%)
Lip Disorder	6 (.62%)
Orthostatic Hypotension	6 (.62%)
Pancreatitis Acute	6 (.62%)
Pneumonia	6 (.62%)
Blood Alkaline Phosphatase Increase...	5 (.51%)
Blood Prolactin Increased	5 (.51%)
C-reactive Protein Increased	5 (.51%)
Coma	5 (.51%)
Constipation	5 (.51%)
Convulsion	5 (.51%)
Dizziness	5 (.51%)
Drug Ineffective	5 (.51%)
Galactorrhoea	5 (.51%)
Gamma-glutamyltransferase Increased	5 (.51%)
Hyperkalaemia	5 (.51%)
Leukopenia	5 (.51%)
Myalgia	5 (.51%)
Tongue Necrosis	5 (.51%)
Toxic Skin Eruption	5 (.51%)
Abdominal Pain	4 (.41%)
Anaemia Haemolytic Autoimmune	4 (.41%)
Anorexia	4 (.41%)
Anticoagulation Drug Level Above Th...	4 (.41%)
Cardiac Arrest	4 (.41%)
Cholelithiasis	4 (.41%)
Drug Interaction	4 (.41%)
Dyspepsia	4 (.41%)
Eructation	4 (.41%)
Fungal Infection	4 (.41%)
Gait Disturbance	4 (.41%)
Gastrointestinal Disorder	4 (.41%)
Gastrooesophageal Reflux Disease	4 (.41%)
Haematoma	4 (.41%)
Hypersensitivity	4 (.41%)
Hypokalaemia	4 (.41%)
Infection	4 (.41%)
Leukocytosis	4 (.41%)
Lip Oedema	4 (.41%)
Lung Disorder	4 (.41%)
Oedema	4 (.41%)
Pain	4 (.41%)
Renal Failure Acute	4 (.41%)
Rhabdomyolysis	4 (.41%)
Serotonin Syndrome	4 (.41%)
Thrombocytopenia	4 (.41%)
Tongue Biting	4 (.41%)
Urinary Tract Infection	4 (.41%)
Abdominal Discomfort	3 (.31%)
Abnormal Behaviour	3 (.31%)
Back Pain	3 (.31%)
Bacterial Infection	3 (.31%)
Blood Chloride Decreased	3 (.31%)
Bradycardia	3 (.31%)
Bronchial Obstruction	3 (.31%)
Bronchitis	3 (.31%)
Cerebrovascular Accident	3 (.31%)
Cheilitis	3 (.31%)
Colitis	3 (.31%)
Condition Aggravated	3 (.31%)
Drug Withdrawal Syndrome	3 (.31%)
Face Oedema	3 (.31%)
Fine Motor Delay	3 (.31%)
Gastrointestinal Sounds Abnormal	3 (.31%)
Haematuria	3 (.31%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Stablon, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Stablon is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Stablon

What are the most common Stablon adverse events reported to the FDA?

Epidermal And Dermal Conditions	65 (6.67%)
Gastrointestinal Signs	61 (6.26%)
Electrolyte And Fluid Balance Condi...	55 (5.65%)
White Blood Cell	39 (4%)
Hepatic And Hepatobiliary	35 (3.59%)
Neurological	33 (3.39%)
Respiratory	31 (3.18%)
Infections - Pathogen Unspecified	28 (2.87%)
Gastrointestinal Motility And Defec...	27 (2.77%)
Injuries	27 (2.77%)
Deliria	23 (2.36%)
	Show More
Body Temperature Conditions	22 (2.26%)
Anemias Nonhemolytic And Marrow Dep...	18 (1.85%)
Central Nervous System Vascular	18 (1.85%)
Hematology Investigations	18 (1.85%)
Musculoskeletal And Connective Tiss...	17 (1.75%)
Oral Soft Tissue Conditions	17 (1.75%)
Hepatobiliary	16 (1.64%)
Metabolic, Nutritional And Blood Ga...	13 (1.33%)
Seizures	13 (1.33%)
Movement Disorders	12 (1.23%)
Muscle	12 (1.23%)
Therapeutic And Nontherapeutic Effe...	12 (1.23%)
Renal Disorders	11 (1.13%)
Food Intolerance Syndromes	10 (1.03%)
Tongue Conditions	9 (.92%)
Cardiac Arrhythmias	8 (.82%)
Suicidal And Self-injurious Behavio...	8 (.82%)
Vascular Hypertensive	8 (.82%)
Cardiac And Vascular Investigations	7 (.72%)
Decreased And Nonspecific Blood Pre...	7 (.72%)
Enzyme	7 (.72%)
Exocrine Pancreas Conditions	7 (.72%)
Appetite And General Nutritional	6 (.62%)
Fungal Infectious	6 (.62%)
Medication Errors	6 (.62%)
Neuromuscular	6 (.62%)
Peripheral Neuropathies	6 (.62%)
Protein And Chemistry Analyses	6 (.62%)
Water, Electrolyte And Mineral	6 (.62%)
Breast	5 (.51%)
Bronchial Disorders	5 (.51%)
Endocrine Investigations	5 (.51%)
Hemolyses And Related Conditions	5 (.51%)
Physical Examination Topics	5 (.51%)
Renal And Urinary Tract Investigati...	5 (.51%)
Sleep Disorders	5 (.51%)
Toxicology And Therapeutic Drug Mon...	5 (.51%)
Allergic Conditions	4 (.41%)
Bacterial Infectious	4 (.41%)
Bone And Joint Injuries	4 (.41%)
Fatal Outcomes	4 (.41%)
Gallbladder	4 (.41%)
Gastrointestinal Conditions	4 (.41%)
Gastrointestinal Inflammatory Condi...	4 (.41%)
Mental Impairment	4 (.41%)
Myocardial	4 (.41%)
Platelet	4 (.41%)
Vascular Hemorrhagic	4 (.41%)
Cornification And Dystrophic Skin	3 (.31%)
Depressed Mood Disorders	3 (.31%)
Encephalopathies	3 (.31%)
Gastrointestinal Hemorrhages	3 (.31%)
Gastrointestinal Stenosis And Obstr...	3 (.31%)
Inner Ear And Viiith Cranial Nerve	3 (.31%)
Lower Respiratory Tract Disorders	3 (.31%)
Psychiatric And Behavioural Symptom...	3 (.31%)
Urinary Tract Signs	3 (.31%)
Abdominal Hernias And Other Abdomin...	2 (.21%)
Arteriosclerosis, Stenosis, Vascula...	2 (.21%)
Aural	2 (.21%)
Changes In Physical Activity	2 (.21%)
Chemical Injury And Poisoning	2 (.21%)
Eating Disorders	2 (.21%)
Endocrine Neoplasms Malignant And U...	2 (.21%)
Gastrointestinal Neoplasms Malignan...	2 (.21%)
Gastrointestinal Ulceration And Per...	2 (.21%)
Heart Failures	2 (.21%)
Lifestyle Issues	2 (.21%)
Metabolism	2 (.21%)
Microbiology And Serology	2 (.21%)
Mood Disorders	2 (.21%)
Neonatal And Perinatal Conditions	2 (.21%)
Neurological Disorders Of The Eye	2 (.21%)
Ocular Neuromuscular	2 (.21%)
Reproductive Tract	2 (.21%)
Upper Respiratory Tract Disorders	2 (.21%)
Anxiety Disorders	1 (.1%)
Bladder And Bladder Neck Disorders	1 (.1%)
Cardiac Disorder Signs	1 (.1%)
Cranial Nerve Disorders	1 (.1%)
Disturbances In Thinking	1 (.1%)
Diverticular	1 (.1%)
Ear And Labyrinthine Disorders Cong...	1 (.1%)
Gastrointestinal	1 (.1%)
Hematological	1 (.1%)
Immunology And Allergy	1 (.1%)
Investigations, Imaging And Histopa...	1 (.1%)
Leukemias	1 (.1%)
Musculoskeletal And Soft Tissue Inv...	1 (.1%)
Pleural	1 (.1%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Stablon, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Stablon is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.